Friday, March 31, 2023 Daily Archives

IDT Biologika on the major role of oncolytic viruses in CGT development

by

IDT Biologika is a globally operating biopharmaceutical CDMO that specializes in the Contract Development and Manufacturing of cell & gene therapeutics including oncolytic viruses and viral vectors, and innovative vaccines. Through the utilization of our innovative technologies, we help our clients to advance their prophylactic and therapeutic products to treat serious diseases that impact human health worldwide. Learn more how IDT Biologika can advance your Cell & Gene Therapy projects by the following two articles: Bringing vector-based products to market…

March 31, 2023

Celltrion eyes US biomanufacturing plant on back of Biden’s Executive Order

by

With the US Government pushing a domestic biomanufacturing policy, Korean drugmaker Celltrion says it assessing building a facility in the country. In September last year, US President Joe Biden signed an Executive Order to advance domestic biotechnology and biomanufacturing innovation. The White House has further advanced its position through the publication of a series of goals and priorities this month to support the Order. In a press conference Wednesday, Celltrion Group Chairman Seo Jung-jin said the Korean firm is “keeping a close…

March 31, 2023

Sartorius to add CGT reagents through $2.6bn Polyplus buy

by

The acquisition will bring Sartorius a range of transfection reagents and plasmids and, at €2.4 ($2.6) billion, is the largest bolt-on for the bioprocess vendor. The deal announced Friday will see Sartorius subsidiary Sartorius Stedim Biotech (SSB) buy France-based Polyplus, adding a range of components used in the production of viral vectors and around 270 staff members. René Fáber, who recently tookover as CEO of SSB from Joachim Kreuzburg, described Polyplus’ offerings as “highly complementary to our portfolio, in particular…

March 31, 2023

Pharmaron to expand UK gene therapy biz at ex-AbbVie plant

by

CDMO Pharmaron Beijing has ploughed £151 million ($186 million) into a former-AbbVie facility in Liverpool, UK. China-owned Pharmaron acquired the facility from AbbVie in March 2021 for $119 million, propelling it into the cell and gene therapy (CGT) manufacturing space. Now the contract development manufacturing organization (CDMO) is building an additional 86,000 square-foot viral vector and DNA manufacturing facility, bringing a four-fold increase in gene therapy process development and analytical capacity accommodating DNA and RNA drug substance, as well as viral…

March 31, 2023